COVID-19 与癌症：我们真的了解我们自以为了解的吗？
COVID-19 and cancer: do we really know what we think we know?
机构信息
Department of Oncology, Queen's University, Kingston, ON, Canada.
Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Queen's University, Kingston, ON, Canada.
出版信息
Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. doi: 10.1038/s41571-020-0394-y.
Abstract
Early published data on COVID-19 in patients with cancer are being referenced in clinical guidelines, despite methodological flaws that limit the quality of much of this evidence. In the next phase of research in this area, we argue that the quality of observational evidence should be prioritized over speed of publication.
摘要
早期发表的关于癌症患者 COVID-19 的数据被临床指南引用，尽管这些数据存在方法学缺陷，限制了大部分证据的质量。在该领域的下一阶段研究中，我们认为观察性证据的质量应该优先于发表速度。
相似文献
1
COVID-19 and cancer: do we really know what we think we know?COVID-19 与癌症：我们真的了解我们自以为了解的吗？
Nat Rev Clin Oncol. 2020 Jul;17(7):386-388. doi: 10.1038/s41571-020-0394-y.
2
Challenges Faced by Medical Journals During the COVID-19 Pandemic.新冠疫情期间医学期刊面临的挑战
J Clin Oncol. 2020 Jul 1;38(19):2206-2207. doi: 10.1200/JCO.20.00858. Epub 2020 Apr 8.
3
COVID-19 in a Kidney Transplant Patient.一名肾移植患者的新型冠状病毒肺炎
Eur Urol. 2020 Jun;77(6):769-770. doi: 10.1016/j.eururo.2020.03.036. Epub 2020 Apr 6.
4
COVID-19-related Mortality During the First 60 Days After Kidney Transplantation.肾移植后前60天内与COVID-19相关的死亡率
Eur Urol. 2020 Oct;78(4):641-643. doi: 10.1016/j.eururo.2020.06.036. Epub 2020 Jun 19.
5
[COVID-19- what have we learned and where are we heading?].[新冠疫情——我们学到了什么，又将走向何方？]
Laeknabladid. 2020 Oct;106(10):449. doi: 10.17992/lbl.2020.10.598.
6
Coronavirus Disease 2019 (COVID-19) and Immune-Engaging Cancer Treatment.2019冠状病毒病（COVID-19）与免疫参与性癌症治疗
JAMA Oncol. 2020 Oct 1;6(10):1529-1530. doi: 10.1001/jamaoncol.2020.2367.
7
8
Triage of patients with COVID-19.新型冠状病毒肺炎患者的分诊
Br J Gen Pract. 2020 Jun 25;70(696):327. doi: 10.3399/bjgp20X710825. Print 2020 Jul.
9
Hematopoietic stem cell transplantation dilemma during the COVID-19 era.新冠疫情时代造血干细胞移植的困境
Future Oncol. 2020 Aug;16(22):1569-1573. doi: 10.2217/fon-2020-0414. Epub 2020 May 27.
10
The Early Days: The Postkidney Transplant Recipients' COVID-19 Journey.早期：肾移植受者的新冠疫情经历
Clin J Am Soc Nephrol. 2020 Sep 7;15(9):1221-1223. doi: 10.2215/CJN.08780620. Epub 2020 Jul 29.
引用本文的文献
1
Impact of SARS-CoV-2 vaccines and recent chemotherapy on COVID-19 morbidity and mortality in patients with soft tissue sarcoma: an analysis from the OnCovid registry.严重急性呼吸综合征冠状病毒2型（SARS-CoV-2）疫苗及近期化疗对软组织肉瘤患者新型冠状病毒肺炎（COVID-19）发病率和死亡率的影响：来自OnCovid注册研究的分析
Ther Adv Med Oncol. 2024 Jan 18;16:17588359231225028. doi: 10.1177/17588359231225028. eCollection 2024.
2
Antibody Response to COVID-19 mRNA Vaccines in Oncologic and Hematologic Patients Undergoing Chemotherapy.肿瘤和血液系统疾病患者在接受化疗期间针对 COVID-19 mRNA 疫苗的抗体反应。
Curr Oncol. 2022 May 6;29(5):3364-3374. doi: 10.3390/curroncol29050273.
3
Global cancer research in the era of COVID-19: a bibliometric analysis.新冠疫情时代的全球癌症研究：一项文献计量分析
Ecancermedicalscience. 2021 Jul 7;15:1264. doi: 10.3332/ecancer.2021.1264. eCollection 2021.
4
The risks associated with the widespread use of telemedicine in oncology: Four cases and review of the literature.肿瘤学中远程医疗广泛应用相关的风险：4 个案例及文献复习。
Cancer Rep (Hoboken). 2022 Jul;5(7):e1531. doi: 10.1002/cnr2.1531. Epub 2021 Aug 18.
5
Seroprevalence of SARS-CoV-2-Specific Antibodies in Cancer Patients Undergoing Active Systemic Treatment: A Single-Center Experience from the Marche Region, Italy.接受积极全身治疗的癌症患者中新冠病毒 2 型特异性抗体的血清流行率：来自意大利马尔凯地区的单中心经验
J Clin Med. 2021 Apr 4;10(7):1503. doi: 10.3390/jcm10071503.
6
A Systematic Review and Meta-Analysis of Cancer Patients Affected by a Novel Coronavirus.新型冠状病毒感染癌症患者的系统评价和荟萃分析。
JNCI Cancer Spectr. 2021 Feb 24;5(2):pkaa102. doi: 10.1093/jncics/pkaa102. eCollection 2021 Apr.
7
Cumulative COVID-19 incidence, mortality and prognosis in cancer survivors: A population-based study in Reggio Emilia, Northern Italy.癌症幸存者中新冠病毒病的累积发病率、死亡率及预后：意大利北部雷焦艾米利亚的一项基于人群的研究
Int J Cancer. 2021 Apr 16;149(4):820-6. doi: 10.1002/ijc.33601.
8
Narrative review of lung cancer treatment at the time of COVID-19 pandemia: pitfall and issues.2019冠状病毒病大流行期间肺癌治疗的叙述性综述：陷阱与问题
Transl Lung Cancer Res. 2021 Jan;10(1):475-482. doi: 10.21037/tlcr-20-640.
9
Cancer and Immune Checkpoint Inhibitor Treatment in the Era of SARS-CoV-2 Infection.SARS-CoV-2感染时代的癌症与免疫检查点抑制剂治疗
Cancers (Basel). 2020 Nov 16;12(11):3383. doi: 10.3390/cancers12113383.
10
COVID-19 in cancer patients on systemic anti-cancer therapies: outcomes from the CAPITOL (COVID-19 Cancer PatIenT Outcomes in North London) cohort study.接受全身抗癌治疗的癌症患者中的 COVID-19：来自 CAPITOL（北伦敦 COVID-19 癌症患者结局）队列研究的结果。
Ther Adv Med Oncol. 2020 Oct 23;12:1758835920971147. doi: 10.1177/1758835920971147. eCollection 2020.
本文引用的文献
1
Evaluation of First-line Radiosurgery vs Whole-Brain Radiotherapy for Small Cell Lung Cancer Brain Metastases: The FIRE-SCLC Cohort Study.小细胞肺癌脑转移一线立体定向放疗与全脑放疗的评价：FIRE-SCLC 队列研究。
JAMA Oncol. 2020 Jul 1;6(7):1028-1037. doi: 10.1001/jamaoncol.2020.1271.
2
Enrichment of kinase fusions in ESR1 wild-type, metastatic breast cancer revealed by a systematic analysis of 4854 patients.对4854例患者的系统分析揭示了ESR1野生型转移性乳腺癌中激酶融合的富集情况。
Ann Oncol. 2020 Aug;31(8):991-1000. doi: 10.1016/j.annonc.2020.04.008. Epub 2020 Apr 26.
3
Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak.癌症患者似乎更容易感染 SARS-CoV-2：COVID-19 爆发期间的一项多中心研究。
Cancer Discov. 2020 Jun;10(6):783-791. doi: 10.1158/2159-8290.CD-20-0422. Epub 2020 Apr 28.
4
Do patients with cancer have a poorer prognosis of COVID-19? An experience in New York City.癌症患者的新冠病毒病预后是否更差？纽约市的一项经验。
Ann Oncol. 2020 Aug;31(8):1088-1089. doi: 10.1016/j.annonc.2020.04.006. Epub 2020 Apr 21.
Zotero 插件